Crimson Publishers Publish With Us Reprints e-Books Video articles


Open Access Biostatistics & Bioinformatics

Quinacrine and Berberine as Antiviral Agents against Dengue and Zika Fever: In Silico Approach

  • Open or Close Vivek Srivastava*

    Department of Biotechnology, Rama University, India

    *Corresponding author: Vivek Srivastava, Department of Biotechnology, Faculty of Engineering & Technology, Rama University Uttar Pradesh Kanpur, India

Submission: June 15, 2018; Published: July 25, 2018

DOI: 10.31031/OABB.2018.02.000532

ISSN 2578-0247
Volume2 Issue2


Dengue and Zika fever are mosquito-borne viral diseases that have rapidly spread in all over world. Currently there are no specific drugs for DENV and ZIKV infection. The recent outbreak of these viruses realized that there are major health risks, demands an enhanced surveillance and a need to develop novel drugs against them. Non-structural proteins NS5 and NS3 are essential for the replication of the flavi-viral RNA genome. Therefore its inhibition could be considered as a useful strategy for treatment of DENV and ZIKV infection. Quinacrine and Berberine had been docked with NS5-methyltransferase of Dengue virus and NS3 protein of ZIKV using Auto dock 4.2 tools. Quinacrine and Berberine showed binding affinity -6.83kcal/mol and -6.22kcal/mol with NS5-methyltransferase and -7.32kcal/mol and -8.03kcal/mol with NS3 protease of ZIKV, respectively. Observations discussion in review will be useful in designing single drug against both virus infections..

Keywords: NS3 protease; NS5-methyltransferase; Antiviral drugs; Dengue virus; Zika virus

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137